and more selective therapeutic strategies for these diseases.
Persistent, chronic inflammatory diseases, such as systemic lupus erythematosus and psoriasis, are thought to involve different types of immune cells whose specific effector functions contribute to the development of disease. Innate immune cells, such as macrophages and granulocytes, produce a variety of factors upon Toll-like receptor activation, including cytotoxic substances and antimicrobial peptides, which they normally use to combat infectious agents but which may damage host tissue as bystander effect. Other immune cells, known as "B-lymphocytes," produce molecules called "antibodies," which bind and inactivate pathogens but under certain circumstances may be directed against host tissue, including DNA, a phenomenon typically found in patients who have systemic lupus erythematosus.
Systemic lupus erythematosus can affect almost any organ, including skin, brain, joints, and kidney. Psoriasis is limited initially to the skin but progresses toward arthritis in as many as 10-30% of cases. The two diseases seem to involve similar mechanisms. First, tissue injury, e.g., during an infectious challenge, leads to release of host factors, including DNA and/or RNA, that form complexes with autoreactive antibodies (systemic lupus erythematosus) or antimicrobial Model of ABIN1 function in Toll-like receptor signaling and inflammation. Toll-like receptor stimulation in innate immune cells leads to the formation of a signaling complex that contains defined proteins, such as MyD88, members of the IL-1 receptorassociated kinase (IRAK) family and TNF-associated factor 6 (TRAF6), and also leads to recruitment of ABIN1. ABIN1-deficient cells show increased C/EBPβ activity upon Toll-like receptor stimulation; this increased activity leads to increased expression of bona fide C/EBPβ target genes, including those encoding C/EBPβ itself, S100A8, nitric oxide species, and G-CSF. Meanwhile, other major proinflammatory signaling pathways, including the NF-κB and AP-1 pathways, proceed normally, and their target genes are expressed at normal or even reduced levels. Inadequately produced factors encoded by C/EBPβ target genes may promote and perpetuate Toll-like receptor-mediated inflammation, either via direct TLR4 activation (S100A8) or TLR7/9 activation through nucleic acids (DNA/RNA, possibly in complex with autoreactive antibodies or antimicrobial peptides) that are released from cells upon NO-mediated tissue damage. G-CSF may fuel inflammation further through complex proinflammatory functions that include increased production of myeloid cells.
peptides (psoriasis and systemic lupus erythematosus). Next, these complexes trigger the activity of specific Toll-like receptors, such as TLR9 and TLR7, thereby providing a possible link between tissue injury and perpetuation of inflammation (2, 3) . Although such model supports the idea that Toll-like receptors are involved in promoting inflammatory disease, the etiology of both diseases is largely unclear. More specifically, it is unclear what molecular mechanism protects us against such perpetuation of inflammation under normal circumstances and why this mechanism fails in affected patients. Systemic lupus erythematosus and psoriasis involve clear genetic components, as revealed by familial aggregation studies (4). Moreover, a set of recent genome-wide association studies has identified several genes or gene sequences (loci) involved in susceptibility to these diseases, including TNFAIP3-interacting protein 1 (TNIP1), which encodes the protein ABIN1.
ABIN1 had been shown previously to regulate negatively the signaling pathways induced by TNF-α, an important inflammatory cytokine (5); however, the function of ABIN1 in the Toll-like receptor pathway had not been investigated. After we identified ABIN1biochemically as a component in Toll-like receptor signaling pathways, we generated ABIN1-deficient mice to study the function of ABIN1 in vivo and during Toll-like receptor activation. We found that ABIN1-deficient mice developed a progressive, lupus-like inflammatory disease characterized by expansion of myeloid cells, the infiltration of immune cells into different organs such as the kidneys, liver, and lung, the activation of lymphocytes, and the appearance of autoreactive antibodies. Kidneys developed disease, reflected by inflammation (glomerulonephritis) and proteinuria. Surprisingly, ABIN1-deficient macrophages exhibited normal regulation of major proinflammatory signaling pathways, i.e., the NF-κB and MAPK pathways. These mice also showed normal, if not reduced, expression of respective target genes encoding TNF-α, IL-12, and IL-6. However, ABIN1-deficient macrophages exhibited a selective increase in the expression of the transcription factor C/EBPβ and its target genes, such as colony-stimulating factor 3 (Csf3), nitric oxide synthase 2, inducible (Nos2), and S100 calcium binding protein A8 (S100a8), whose gene products are linked intimately to innate immune cell proliferation (G-CSF), cytotoxicity (nitric oxide species), and host factor-derived inflammation (S100A8). Although the TLR-dependent signal-transduction pathway that controls C/EBPβ activity is largely undefined, it appears that ABIN1 controls the ratio of the two major forms of the mature C/EBPβ protein, i.e., liver-enriched transcriptional activator protein (LAP) and liverenriched inhibitory protein (LIP), favoring expression of the transcriptionally active LAP form. Active C/EBPβ also regulates its own promoter via a characterized feed-forward loop, possibly accounting for the sustained increase of C/EBPβ activity observed in ABIN1-deficient cells.
Together, our data reveal that ABIN1 is an essential antiinflammatory component of the Toll-like receptor signaling pathways controlling the activity of C/EBPβ, whose target genes may explain, at least in part, the chronic inflammatory response in ABIN1-deficient mice. Based on these data, we propose a model for inflammatory disease development depicted in Fig. P1 . In this model, we propose the deregulation of Toll-like receptor signaling pathways in innate immune cells as an initiating factor. Importantly, in contrast to other models based on mutations in other negative regulatory molecules and the suspected role of major proinflammatory signaling pathways (e.g., the NF-κB and MAPK pathways), this model emphasizes the role of the C/EBPβ pathway and a rather select set of Toll-like receptor-induced functions as potential culprits in inflammatory disease development. Given the genetic link between ABIN1 (TNIP1) and human systemic lupus erythematosus, the observations made in ABIN1-deficient mice may have important implications for human disease and the development of novel, possibly more selective therapeutic strategies.
